Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 55Neoplasms, Plasma Cell 22Central Nervous System Neoplasms 10Prostatic Neoplasms 9Glioblastoma 9Recurrence 8Melanoma 8Brain Neoplasms 8Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 6Leukemia 6Carcinoma, Hepatocellular 6Waldenstrom Macroglobulinemia 5Myeloproliferative Disorders 5Lung Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Glioma 5Colorectal Neoplasms 5Myelodysplastic-Myeloproliferative Diseases 4Myelodysplastic Syndromes 4Lymphoma 4Liver Neoplasms 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myelomonocytic, Chronic 3

Interventions

Dexamethasone 10Bortezomib 7Lenalidomide 4isatuximab 3Calcium Dobesilate 3pomalidomide 2Thalidomide 2Gemcitabine 2Cyclophosphamide 2vinflunine 1melflufen 1glucarpidase 1gallium 68 PSMA-11 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Tablets 1Ranitidine 1Pluvicto 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Eplerenone 1Doxorubicin 1Diphenhydramine 1Carboplatin 1Bendamustine Hydrochloride 1BHQ880 1Acetaminophen 1ARQ 197 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Renal Insufficiency × Thalidomide × Clear all
NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Emory University

Phase 2 Terminated
17 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT02424851 2022-01-27

OPTIMAL

Oxford University Hospitals NHS Trust

Phase 2 Completed
31 enrolled 13 charts
Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡